Regenecyte is under clinical development by StemCyte and currently in Pre-Registration for Unspecified Hematological Disorders. According to GlobalData, Pre-Registration drugs for Unspecified Hematological Disorders does not have sufficient historical data to build an indication benchmark PTSR for Pre-Registration. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Regenecyte LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Regenecyte overview
The therapeutic candidate (Regenecyte) is under development for the treatment of hematopoietic system diseases, unspecified immunological disorders, unspecified metabolic disorders, acute ischemic stroke, cerebral palsy and post-COVID syndrome, long crown syndrome. The therapeutic candidate comprises of allogeneic human umbilical cord blood hematopoietic stem cells, administered through parenteral route.
StemCyte overview
StemCyte is a global regenerative therapeutics company specializing in the preservation and application of stem cells derived from umbilical cord blood and tissue. The company provides both private and public cord blood banking services and participating in clinical trials to explore new treatments using stem cells. StemCyte offers services such as cord blood and cord tissue banking, along with newborn genetic analysis (NGA) and human leukocyte antigen (HLA) testing. The company’s services are utilized by families seeking to preserve stem cells for potential future medical treatments including cancer and blood disorders. StemCyte is headquartered in Baldwin Park, California, the US.
For a complete picture of Regenecyte’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
